Clinical use of intravenous immunoglobulins
Related Experiment Video
Updated: Oct 13, 2026

Assessment of Antibody-based Drugs Effects on Murine Bone Marrow and Peritoneal Macrophage Activation
Published on: December 26, 2017
U E Nydegger1, P J Mohacsi, R Escher
1Clinic of Cardiovascular Surgery, University Hospital Bern, Switzerland. urs.nydegger@insel.ch
Prophylaxis and treatment with i.v. immunoglobulins must envisage preparations from normal or hyperimmunised human donors, animals (horses and rabbits) as well as monoclonal and genetically and proteomically engineered chimeric or recombinant antibodies. The latter group of antibody sources from the bioreactor source must be seen in the context of traditional antibody therapy, including passive immunization, general antibody substitution and provision of lost immune regulatory capacities such as downregulation of complement activation, attenuation of Fc receptor apparatus as well as anti-idiotypic potential. Beyond summarizing the present evidence based indications the present review is an outlook at the doorstep for future possibilities to improve precision of antibody dependent treatments and avoiding side effects which formerly compromised widespread use.
Prophylaxis and treatment with i.v. immunoglobulins must envisage preparations from normal or hyperimmunised human donors, animals (horses and rabbits) as well as monoclonal and genetically and proteomically engineered chimeric or recombinant antibodies. The latter group of antibody sources from the bioreactor source must be seen in the context of traditional antibody therapy, including passive immunization, general antibody substitution and provision of lost immune regulatory capacities such as downregulation of complement activation, attenuation of Fc receptor apparatus as well as anti-idiotypic potential. Beyond summarizing the present evidence based indications the present review is an outlook at the doorstep for future possibilities to improve precision of antibody dependent treatments and avoiding side effects which formerly compromised widespread use.
Related Concept Videos
Inhibitors of Viral Protein Synthesis
Immunodeficiency Diseases
There are three main causes of immunodeficiency disorders...
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Drug Product Performance: In Vitro–In Vivo Correlation
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

